UNITY Biotechnology Inc: Ongoing Phase 2B Aspire Study of Ubx1325 Has Been Extended From 24 to 36 Weeks
UNITY Biotechnology Inc:正在进行的Ubx1325的2B期Aspire研究已从24周延长至36周
UNITY Biotechnology Inc: Ongoing Phase 2B Aspire Study of Ubx1325 Has Been Extended From 24 to 36 Weeks
UNITY Biotechnology Inc:正在进行的Ubx1325的2B期Aspire研究已从24周延长至36周
使用浏览器的分享功能,分享给你的好友吧